We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+11.2%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$9.54B
AUM Growth
+$718M
Cap. Flow
-$27.8M
Cap. Flow %
-0.29%
Top 10 Hldgs %
34.85%
Holding
152
New
15
Increased
35
Reduced
32
Closed
15

Top Buys

Rank Stock Value
1
CI icon
Cigna
CI
+$196M
2
CLVS
Clovis Oncology, Inc.
CLVS
+$129M
3
GILD icon
Gilead Sciences
GILD
+$84.7M
4
VTRS icon
Viatris
VTRS
+$64.4M
5
BIIB icon
Biogen
BIIB
+$51.1M

Top Sells

Rank Stock Value
1
CNC icon
Centene
CNC
+$118M
2
PFE icon
Pfizer
PFE
+$98M
3
HCA icon
HCA Healthcare
HCA
+$97.1M
4
THC icon
Tenet Healthcare
THC
+$94.8M
5
AGN.PRA
Allergan plc
AGN.PRA
+$73.9M

Sector Composition

Rank Sector Weight
1 Healthcare 92.6%
2 Financials 1.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALXN
1
DELISTED
Alexion Pharmaceuticals
ALXN
$471M 4.94%
3,871,786
+160,800
+4% +$18.7M
CELG
2
DELISTED
Celgene Corp
CELG
$445M 4.66%
3,425,777
+293,600
+9% +$36M
BIIB icon
3
Biogen
BIIB
$32B
$442M 4.64%
1,630,000
+193,100
+13% +$51.1M
BSX icon
4
Boston Scientific
BSX
$68.9B
$399M 4.18%
14,400,000
-911,400
-6% -$24.2M
MRK icon
5
Merck
MRK
$324B
$352M 3.69%
5,750,376
-238,839
-4% -$14.5M
VRTX icon
6
Vertex Pharmaceuticals
VRTX
$124B
$261M 2.74%
2,026,502
-142,698
-7% -$17.2M
LLY icon
7
Eli Lilly
LLY
$1.09T
$253M 2.65%
3,075,000
-255,200
-8% -$20.8M
WMGI
8
DELISTED
Wright Medical Group Inc
WMGI
$246M 2.58%
8,946,234
– –
REGN icon
9
Regeneron Pharmaceuticals
REGN
$73.1B
$229M 2.4%
466,770
+88,600
+23% +$38.8M
A icon
10
Agilent Technologies
A
$39.6B
$226M 2.37%
3,814,100
+184,200
+5% +$10.5M
AMGN icon
11
Amgen
AMGN
$212B
$224M 2.35%
1,302,700
-135,600
-9% -$22.1M
EW icon
12
Edwards Lifesciences
EW
$49.2B
$217M 2.28%
5,517,900
– –
PBYI icon
13
Puma Biotechnology
PBYI
$398M
$212M 2.22%
2,425,735
+179,810
+8% +$10.1M
INCY icon
14
Incyte
INCY
$25.3B
$209M 2.2%
1,663,400
-310,197
-16% -$39.5M
CI icon
15
Cigna
CI
$78.9B
$205M 2.14%
+1,222,100
New +$196M
CLVS
16
DELISTED
Clovis Oncology, Inc.
CLVS
$197M 2.07%
+2,104,370
New +$129M
HUM icon
17
Humana
HUM
$43.8B
$185M 1.94%
770,900
+28,600
+4% +$6.48M
ELV icon
18
Elevance Health
ELV
$82.9B
$173M 1.82%
920,618
+58,018
+7% +$10.4M
ABBV icon
19
AbbVie
ABBV
$471B
$159M 1.67%
2,197,600
+117,600
+6% +$7.91M
JNJ icon
20
Johnson & Johnson
JNJ
$644B
$149M 1.56%
1,124,400
+239,800
+27% +$30.6M
GILD icon
21
Gilead Sciences
GILD
$166B
$147M 1.54%
2,073,400
+1,272,500
+159% +$84.7M
LOXO
22
DELISTED
Loxo Oncology, Inc
LOXO
$139M 1.45%
1,728,000
– –
AET
23
DELISTED
Aetna Inc
AET
$135M 1.41%
887,900
-424,500
-32% -$60M
ARRY
24
DELISTED
Array Biopharma Inc
ARRY
$119M 1.24%
14,182,900
– –
VTRS icon
25
Viatris
VTRS
$20.8B
$116M 1.21%
2,979,200
+1,679,200
+129% +$64.4M
1
2 3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q2 2017 Portfolio in Review

As of Q2 2017, OrbiMed held 152 positions worth $9.54B, up 8.1% from $8.82B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

OrbiMed's Q2 2017 filing shows 15 new, 35 increased, 32 reduced and 15 closed positions. Its largest new stake was Cigna: 1,222,100 shares worth $205M. The largest sale was Centene, an estimated $118M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 93% a quarter earlier, followed by Financials.

  • OrbiMed's largest Q2 2017 buy was Cigna: 1,222,100 shares worth $205M.
  • OrbiMed added most to Gilead Sciences in Q2 2017, an estimated $84.7M increase.
  • OrbiMed's biggest Q2 2017 reduction was Pfizer, cutting an estimated $98M.
  • OrbiMed fully exited Centene in Q2 2017, selling an estimated $118M.
  • OrbiMed's ten largest holdings make up 35% of its $9.54B portfolio in Q2 2017.
  • OrbiMed opened 15 new positions and closed 15 in Q2 2017.
  • OrbiMed's portfolio value rose 8.1% quarter-over-quarter to $9.54B.

Based on OrbiMed's 13F filing for Q2 2017, filed 14 Aug 2017.